A 58-year-old man with diabetes and benign prostatic hyperplasia develops acute pyelonephritis with fever (39.5°C), flank pain, and pyuria. Urine culture grows E. coli sensitive to all standard agents. He has normal renal function. What is the drug of choice for empiric treatment of acute pyelonephritis in this patient?

Explanation

## First-Line Treatment of Acute Pyelonephritis **Key Point:** Ceftriaxone (or fluoroquinolones) are the drugs of choice for acute pyelonephritis because they achieve high renal tissue and serum concentrations needed for systemic infection, unlike nitrofurantoin which concentrates only in urine. ### Why NOT Nitrofurantoin? Nitrofurantoin is **contraindicated** in pyelonephritis because: - Poor renal tissue penetration (only achieves high urinary levels) - Inadequate serum concentrations for systemic infection - Risk of treatment failure and sepsis - Designed exclusively for uncomplicated lower UTI ### Recommended Regimens for Acute Pyelonephritis | Agent | Dose | Duration | Setting | Notes | |-------|------|----------|---------|-------| | **Ceftriaxone** | 1–2 g IV daily (or BID if severe) | 10–14 days | Hospitalized/severe | First-line; excellent renal penetration | | **Fluoroquinolone** | Ciprofloxacin 500–750 mg BD (IV/oral) or Levofloxacin 750 mg daily | 10–14 days | Mild–moderate outpatient | Oral step-down after IV loading | | **Aminoglycoside** | Gentamicin 5–7 mg/kg IV daily (± ampicillin) | 10–14 days | Severe/sepsis | Reserved for resistant organisms | | **Nitrofurantoin** | — | — | **NOT for pyelonephritis** | Inadequate tissue penetration | ### Clinical Management Algorithm ```mermaid flowchart TD A[Acute Pyelonephritis + Fever]:::outcome --> B{Severity?}:::decision B -->|Mild–moderate, stable| C[Oral fluoroquinolone ± IV loading]:::action B -->|Moderate–severe, sepsis| D[IV Ceftriaxone or Aminoglycoside]:::action C --> E[Urine/blood culture results]:::outcome D --> E E --> F{Susceptibility}:::decision F -->|E. coli, susceptible| G[Continue empiric agent 10–14 days]:::action F -->|Resistant organism| H[Switch to targeted therapy]:::action ``` **High-Yield:** The minimum duration is 10–14 days for pyelonephritis (vs. 5–7 days for uncomplicated cystitis). Oral step-down after 48–72 hours of IV therapy is acceptable if clinical improvement occurs. **Clinical Pearl:** In India, where fluoroquinolone resistance is rising, ceftriaxone remains the safest empiric choice for hospitalized patients with pyelonephritis. Oral fluoroquinolones are reserved for mild cases or step-down therapy after IV induction. **Warning:** Do not confuse uncomplicated cystitis (nitrofurantoin) with pyelonephritis (cephalosporin/fluoroquinolone). This is a high-yield exam trap. [cite:KD Tripathi 8e Ch 56; Harrison 21e Ch 269]